Basic Fluorouracil Information

• INN (International Nonproprietary Name): Fluorouracil (also known as 5‑Fluorouracil, 5‑FU).
• Brand Names Available In Australia: Efudex (topical 2% and 5%) is listed as available in Australia; generics and IV brands are supplied internationally and may be available through hospital or specialist supply chains.
• ATC Code: L01BC02 (Antineoplastic Agents — Antimetabolites — Pyrimidine Analogues).
• Forms & Dosages: Injection vials commonly 250 mg/5 mL, 500 mg/10 mL, 1 g/20 mL; topical creams 0.5%, 1%, 2%, 4%, 5% in tubes (20–40 g); lotions/solutions such as 0.5% and 4% formulations.
• Manufacturers In Australia: Local manufacturer listings are not specified in the raw data; global manufacturers include Teva, Mylan, Sandoz, Pfizer, Medac, Bristol‑Myers Squibb and others.
• Registration Status In Australia: Registered under S4 (prescription) in Australia.
• OTC / Rx Classification: Prescription only (Rx); not available over‑the‑counter in any formulation.

Key Findings From Recent Trials

Major 2022–2025 Australian & Global Studies

Worried whether topical 5‑FU still has a place among field therapies for sun‑damaged skin?

Recent high‑quality evidence from 2022–2025 reinforces topical fluorouracil’s role for actinic keratosis and superficial basal cell carcinoma.

Australian registry analyses and international randomised controlled trials report similar lesion clearance rates for 5‑FU creams (1–5%) compared with cryotherapy and topical imiquimod for field‑directed actinic keratosis.

Studies consistently show that topical 5‑FU provides better control across a treated field, at the cost of more intense local skin reactions during therapy.

Main Outcomes

Are patients more likely to see durable clearance with cream or spot treatment?

Field‑directed approaches using 5‑FU cream were associated with improved field clearance and reduction in new lesion formation within treated areas compared with single‑lesion cryotherapy in several trials.

Combination topical formulations, such as 5‑FU with salicylic acid (Actikerall in EU studies), demonstrated increased lesion resolution in hyperkeratotic actinic keratoses versus vehicle or monotherapy arms.

Oncology trials continued to refine IV 5‑FU scheduling and to compare IV infusional approaches with oral prodrugs like capecitabine for tolerability and outpatient convenience.

Safety Observations (TGA Reports)

Are there new safety signals clinicians should know?

TGA safety surveillance and published reports between 2022 and 2025 emphasise DPYD‑related severe toxicity risk with systemic 5‑FU and ongoing signals for photosensitivity and severe local reactions with topical use.

TGA and international safety alerts recommend vigilance, reporting of suspected adverse reactions, and pathways for genetic testing when high‑dose protocols are planned.

The World Health Organization continues to list fluorouracil on the Essential Medicines list, supporting its ongoing role in Australian cancer care.

Clinical Mechanism Of Action

Layman’s Explanation

How does 5‑FU actually work against sun‑damaged skin and tumours?

Fluorouracil is a cytotoxic medicine that stops rapidly dividing cells from making new DNA, so sun‑damaged skin cells and certain superficial cancer cells shrink and die.

When applied as a cream the effect is local to the treated skin and systemic absorption is usually low.

When given intravenously the medicine circulates and targets fast‑growing internal tumours.

Scientific Breakdown

What happens at a cellular level when 5‑FU is used?

5‑Fluorouracil is a pyrimidine analogue that is metabolised inside cells to active metabolites including FdUMP and FUTP.

FdUMP inhibits thymidylate synthase, producing thymidine depletion, DNA replication stress and apoptosis in dividing cells.

FUTP is incorporated into RNA, disrupting RNA processing and function.

Pharmacokinetics differ by route: topical formulations (0.5–5%) produce high local tissue concentrations with minimal systemic exposure, while IV vials (250 mg to 1 g strengths) produce systemic plasma levels that are primarily metabolised in the liver by dihydropyrimidine dehydrogenase (DPYD).

DPYD deficiency markedly reduces clearance and increases systemic toxicity risk, which is a major modern safety consideration.

Important interactions include potentiation of warfarin and increased toxicity with agents such as allopurinol and metronidazole.

Scope Of Approved & Off‑Label Use

Australian Approvals (TGA‑Listed, PBS Inclusion)

Can 5‑FU be prescribed for skin lesions and cancers in Australia?

Fluorouracil is TGA‑registered in Australia as S4 prescription‑only for topical management of actinic keratoses and some superficial skin malignancies and for intravenous use in colorectal, gastric and breast cancers.

Topical brands referenced internationally include Efudex (2% and 5%), Fluoroplex, Carac (0.5%) and Actikerall (0.5% with salicylic acid), while injection vials commonly come in 250 mg to 1 g strengths.

PBS inclusion varies by formulation and indication; systemic oncology indications using IV 5‑FU are commonly PBS‑subsidised under specific regimens, while topical creams may not be universally subsidised for primary skin lesions.

Notable Off‑Label Trends In Australian Practice

Are GPs and dermatologists doing anything different from TGA labels?

Dermatologists and rural GPs often use topical 5‑FU off‑label for field cancerisation and multiple actinic keratoses, following established protocols.

Telehealth dermatology services increasingly issue electronic prescriptions for topical 5‑FU, and community pharmacists play a vital role in counselling patients on application technique and sun protection.

In oncology practice capecitabine is frequently used as an oral alternative to IV 5‑FU to allow outpatient treatment, although substitution depends on the regimen.

DPYD pre‑treatment genotyping is being recommended more frequently for high‑dose systemic protocols, although implementation across Australia remains variable.

Dosage Strategy

General Dosing

How should patients expect to use topical and systemic 5‑FU?

Topical fluorouracil is available in 0.5–5% formulations and is typically applied once or twice daily for 2–6 weeks depending on the product and lesion location.

Systemic dosing is protocol‑driven and uses IV vials (250 mg–1 g); regimens may be bolus or infusion based on tumour type and combination therapy.

A historical systemic bolus example from reference protocols is 12 mg/kg/day (maximum 800 mg/day) IV bolus for four days, followed by 6 mg/kg every other day for additional doses — but actual oncology regimens vary considerably by indication.

Condition‑Specific Dosing (PBS Recommendations)

What are common schedules for skin lesions and hospital chemotherapy courses?

For actinic keratosis and superficial basal cell carcinoma, topical 5‑FU creams such as Efudex 5% are commonly prescribed once or twice daily for 2–6 weeks, with duration adjusted for face versus scalp.

PBS‑subsidised IV oncology regimens specify drug combinations, schedules and eligibility criteria (for example FOLFOX combinations and other defined protocols) and require authority prescriptions.

Dose adjustments are made for severe hepatic impairment, renal compromise, elderly frailty and confirmed DPYD deficiency.

If a topical dose is missed, patients should apply as soon as they remember unless it is close to the next scheduled application.

For missed IV doses the oncology team should be contacted and doses should not be doubled.

Safety Protocols

Contraindications (Australian Guidelines)

Who should never use fluorouracil?

Absolute contraindications include known hypersensitivity to fluorouracil, pregnancy (teratogenic; Category D) and severe bone marrow suppression or active systemic infection.

Relative cautions include significant hepatic or renal impairment, severe cardiac disease, poor nutritional status and concurrent severe illness.

Australian practice follows TGA guidance and oncology protocols for pre‑treatment screening and risk assessment.

Adverse Effects (Post‑Market Pharmacovigilance)

What side effects should patients expect and report?

Topical adverse effects are mainly local and include erythema, burning, pain, desquamation and itching at the application site, with systemic absorption typically minimal unless large areas are treated.

IV therapy is associated with systemic effects such as nausea, vomiting, diarrhoea, stomatitis, myelosuppression, alopecia and photosensitivity, and rare but severe bone marrow failure or neurotoxicity may occur especially in DPYD‑deficient patients.

TGA post‑market reports from 2022–25 highlighted DPYD‑related severe reactions and photosensitivity incidents and recommend that pharmacists and prescribers report suspected adverse events promptly.

Standard practice includes counselling on pregnancy avoidance, contraception, and close monitoring during systemic therapy.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

Will diet change how 5‑FU works or how patients feel?

There are no major food interactions documented for topical fluorouracil.

For systemic 5‑FU alcohol does not markedly change pharmacokinetics but may worsen mucosal irritation such as stomatitis and can increase dehydration risk if diarrhoea occurs, so moderation is advised.

Caffeine intake does not have a direct pharmacokinetic interaction but may exacerbate nausea or jitteriness during chemotherapy for some patients.

Drug Combinations To Avoid (TGA Safety Alerts)

Which medicines increase the risk of harm with 5‑FU?

Clinically important interactions include potentiation of warfarin’s anticoagulant effect and increased bleeding risk when co‑prescribed with systemic 5‑FU.

Co‑administration with allopurinol, metronidazole or other agents that affect pyrimidine metabolism can increase fluorouracil toxicity.

Combining 5‑FU with other myelosuppressive agents requires careful blood count monitoring and oncology supervision.

Community pharmacists in Australia should flag anticoagulant therapy and recent medication changes during counselling and liaise with prescribers when interactions are suspected.

Patient Experience Analysis

Australian Survey Data

What do Australian patients say after using topical 5‑FU?

Surveys and clinic studies from 2022–25 show high satisfaction with field‑directed clearance but regular reports of predictable and sometimes distressing local inflammatory reactions during treatment.

Patients value clear counselling on the expected inflammatory phase, treatment duration of 2–6 weeks and the cosmetic healing timeline after therapy ends.

Rural patients report access barriers such as travel to specialists and delayed prescriptions, increasing reliance on local pharmacists for practical support.

Forum And Pharmacy Trends

What questions turn up most in online forums and at the pharmacy counter?

Online forums mix positive efficacy reports with concerns about pain, prolonged redness and cost, and many patients ask about alternatives such as imiquimod, cryotherapy and photodynamic therapy.

Community pharmacists at chains like TerryWhite, Priceline and Chemist Warehouse frequently advise on application technique, sun protection and checking PBS eligibility for costly topical products.

Telehealth e‑prescribing has improved metropolitan and remote access but reduces opportunities for in‑person application demonstration, increasing the importance of written instructions and pharmacist follow‑up.

Distribution & Pricing Landscape

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Where do Australians pick up topical 5‑FU?

Topical fluorouracil creams are dispensed through community pharmacies after prescription processing, with major chains like Chemist Warehouse, Priceline and TerryWhite stocking topical brands subject to supply.

Hospital oncology pharmacies supply IV vials for inpatient and outpatient chemotherapy services.

Online Pharmacy Growth And Telehealth E‑Scripts

Can patients order 5‑FU without leaving home?

Telehealth dermatology clinics increasingly send e‑scripts for topical 5‑FU and reputable online pharmacies provide courier delivery to metropolitan and regional addresses.

In our online pharmacy, fluorouracil is supplied with a valid prescription and is delivered discreetly to Australia in 5–14 days.

PBS Vs Private Cost Comparisons

How much will treatment cost out of pocket?

PBS usually subsidises many systemic oncology uses of IV 5‑FU under authority scripts and defined regimens, reducing patient cost for those eligible.

Topical creams for actinic keratosis may not be universally PBS‑subsidised, so private costs vary by brand and pharmacy; patients commonly ask pharmacists for generics to reduce expense.

Rural patients may face extra courier fees and occasional supply delays that increase effective costs compared with metropolitan customers.

Alternative Options

Comparison Of PBS And Non‑PBS Options

Which alternatives should be considered instead of 5‑FU?

PBS‑subsidised systemic alternatives include IV 5‑FU regimens and oral capecitabine (an oral 5‑FU prodrug) for many colorectal and breast cancer indications.

Non‑PBS topical options include branded creams such as Efudex 5% or Carac 0.5% and generics from established manufacturers.

Actikerall (5‑FU 0.5% with salicylic acid) is used in the EU but availability in Australia may be limited, requiring specialist import or compounding in some cases.

Pros And Cons Checklist

What are the practical trade‑offs between options?

• Topical 5‑FU — Pros: effective field therapy, low systemic exposure, strong dermatology evidence.
• Topical 5‑FU — Cons: local inflammation, weeks‑long regimen, variable PBS coverage and out‑of‑pocket cost.
• IV 5‑FU — Pros: proven systemic anticancer activity and PBS funding for many protocols.
• IV 5‑FU — Cons: systemic toxicity risks including DPYD‑related severe reactions, needs oncology supervision.
• Capecitabine — Pros: oral convenience and outpatient‑friendly scheduling.
• Capecitabine — Cons: hand‑foot syndrome and different toxicity profile; not interchangeable for every protocol.

Regulatory Status

TGA Approval Framework

How is fluorouracil regulated in Australia?

Fluorouracil is a TGA‑registered medicine in Australia and is classified S4 prescription‑only.

Registration covers topical creams and systemic injection formulations and is based on submissions demonstrating safety, efficacy and manufacturing quality.

The TGA monitors post‑market safety via the Adverse Event Reporting System and issues safety communications where needed.

PBS Subsidy Process

How does a medicine become subsidised in the PBS?

PBS listing requires evidence of clinical and cost‑effectiveness for specific indications and many systemic oncology regimens using IV 5‑FU have been listed under authority scripts and clinical criteria.

Topical 5‑FU creams are not universally PBS‑subsidised and may be dispensed privately depending on indication and prescriber authority.

Special access schemes and hospital dispensing pathways exist for remote and Aboriginal Community Controlled Health Services where necessary.

Consolidated FAQ

Is topical fluorouracil on the PBS?

Topical 5‑FU is prescription‑only (S4) and PBS coverage varies; systemic oncology uses are more commonly subsidised under authority scripts.

How long will my face be red after topical 5‑FU?

Expect active inflammation for 2–6 weeks during treatment, with ongoing healing afterwards; sunscreen and gentle skin care are important.

Can I use topical 5‑FU in pregnancy?

No; fluorouracil is teratogenic and contraindicated in pregnancy; women of childbearing potential should use effective contraception while on treatment.

Do I need DPYD testing before IV 5‑FU?

DPYD deficiency increases severe toxicity risk and testing is increasingly recommended for high‑dose systemic 5‑FU; oncology teams guide testing per protocol.

Can I buy fluorouracil over the counter?

No; it is prescription‑only (S4) in Australia and must be supplied on a valid prescription.

Visual Guide

What quick visuals help patients understand access and handling?

Suggested infographic panels include a PBS versus private cost flowchart, a pharmacy distribution map showing metropolitan chains versus rural community pharmacies and hospital oncology centres, product visuals listing topical strengths (0.5%, 1%, 2%, 4%, 5%) and common vial strengths (250 mg, 500 mg, 1 g), and a patient counselling timeline for expected local reactions and sun protection steps.

Design notes should clearly label S4 status and contraception warnings and use storage icons for topical and injection products.

Storage & Transport

Household Storage Under Australian Climate

How should people store creams during hot Australian summers?

Topical fluorouracil creams should be stored below 25°C, protected from moisture and heat, with the tube tightly closed and kept out of reach of children.

Advise patients to store tubes in a cool cupboard rather than a car or a hot bathroom to avoid degradation.

Cold‑Chain Logistics For Pharmacies

Do IV vials need refrigeration?

Injection vials are usually stored at 20–25°C and protected from light; they are not routinely refrigerated and must not be frozen.

Hospital pharmacies and distributors maintain ambient‑controlled stock for IV vials, and online orders should use reputable couriers with tracking when extreme heat is expected.

Compounded topical preparations must follow validated storage and handling standards and pharmacists should advise on safe disposal of residual cytotoxic creams.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

What should a pharmacist say at the counter?

Confirm the prescription and indication, explain application frequency (1–2 times daily), set expectations for the inflammatory response and timeline (2–6 weeks), and give clear sun avoidance and sunscreen advice.

Demonstrate a pea‑sized dose for a small lesion and advise patients to wash hands after application and protect treated areas with clothing where possible.

Check concurrent medicines such as warfarin, allopurinol or metronidazole and refer to the prescriber for DPYD/genotyping queries for systemic therapy.

Remind patients about storage below 25°C and contraception needs where applicable, and document counselling in the dispensing record.

National Health Authority Recommendations

Which national recommendations guide practice?

Follow TGA labels and oncology/dermatology clinical guidelines for indication‑specific regimens, and consider DPYD screening for high‑dose systemic protocols as per European guidance and emerging Australian practice.

Use PBS authority codes correctly for subsidised items and ensure rural telehealth consults include written instructions and pharmacist follow‑up to monitor reactions.

Delivery Across Australia

Storage And Transport

What are the key handling points for patients and pharmacies?

Topical creams should be kept below 25°C, away from heat and moisture, and stored out of reach of children.

Injection vials should be kept at 20–25°C, protected from light and must not be frozen.

Pharmacies should monitor ambient storage conditions for IV stock and use validated packaging for couriered supplies when extreme heat is forecast.

Patients should return unused cream to the pharmacy for safe disposal rather than discarding in household rubbish where possible.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

How to make counselling practical and reassuring?

Start by asking what the patient most worries about regarding redness or time off work and tailor counselling accordingly.

Explain the expected sequence: inflammation during treatment, then gradual healing, and provide a written action plan for severe reactions or systemic symptoms.

Check and document other medicines, especially anticoagulants and known interacting drugs, and advise contacting the prescriber if systemic symptoms occur.

National Health Authority Recommendations

What should prescribers and pharmacists follow?

Adhere to TGA product labels for indications and dosing, use PBS authority numbers where required, and consider DPYD screening pathways for high‑dose systemic protocols.

For remote patients ensure telehealth prescriptions include clear written instructions and arrange pharmacist‑led follow‑up to manage application technique and adverse reactions.

Concluding Notes

What is the practical bottom line for patients and prescribers in Australia?

Fluorouracil remains a proven, WHO‑listed essential medicine with established topical efficacy for actinic keratoses and superficial basal cell carcinoma and an essential role in systemic oncology regimens.

Topical therapy gives strong field control at the expense of predictable local inflammation and variable PBS coverage, while systemic use requires oncology oversight and attention to DPYD‑related toxicity risk.

Community pharmacists and telehealth services play a key role in access, counselling and safe handling for both metropolitan and rural Australians.

If in doubt about dosing, interactions or storage, consult your pharmacist or treating specialist and report any suspected adverse effects to the TGA.